Partnership website: https://www.jpiamr.eu/activities/one-health-amr/
The OH AMR partnership aims to coordinate and align activities and funding between countries as well as with the Commission. It will also facilitate national coherence between different services and ministries with responsibility for the various aspects of antimicrobial resistance (AMR) (e.g. human health, agriculture, environment, industry, finances).
The main goal is to contribute to achieving the objectives of the European One Health Action Plan against AMR and the WHO Global Action Plan on AMR, by reducing the threat of AMR.
Commission services: RTD-COMBATTING-DISEASES@ec.europa.eu
Contact JPIAMR: ohamr@vr.se
Partnerships group the EC and private and/or public partners, to coordinate and streamline the research & innovation initiatives and funding in some selected key domains.
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.